Please ensure Javascript is enabled for purposes of website accessibility

3 Tips for COVID Vaccine Stock Investing Right Now

By Adria Cimino - Updated Jun 23, 2021 at 8:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coronavirus vaccine investing is far from over.

It's been about a year since people started investing in coronavirus vaccine stocks. And there still is plenty of opportunity in these sorts of shares -- for investors who like risk and those who don't. In this Motley Fool Live video recorded on May 28, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool contributor Adria Cimino discuss three things to keep in mind before investing in coronavirus vaccine stocks today.

Olivia Zitkus: I would love if you could share with all of us three big takeaways, big-picture things to walk away from this conversation with healthcare investors. That will be awesome.

Adria Cimino: Sure, sure. OK, well, the first thing I would say is look at market potential when you're going to invest in a company. Can a particular company actually carve out market share. Like one company that has gained a lot recently is Ocugen (OCGN 5.97%). They have rights to a COVID vaccine to sell in the U.S. But that's going to be a difficult market because the U.S. already has enough vaccines. So that might be a bit difficult and so that's something to keep in mind when you're investing. The second thing is to look at the whole pipeline. Don't just look at the coronavirus vaccine or just any one candidate. It's good to like the general thing, what the company is doing -- to believe in their program rather than just in one product. That's a safer bet. Finally, there are risky and less risky bets in this space. Now it's not like you have to just be a high-risk investor to invest in coronavirus vaccine stocks. Like Moderna (MRNA -0.37%) is not all that risky now. They have a product out in the market and they are making a lot of money on it. So that could be an option for an investor who likes a safer bet.

Zitkus: Awesome. Sweet. So, look at your market potential, don't count on just the vaccine alone, look at the entire pipeline. There's something for everyone. [laughs] That's the takeaway. On the risk spectrum there is something for everybody in the vaccine market. Even though for a while there it was mostly a risky bet. [laughs]

Cimino: Absolutely. I'd say if you invest in something like Vaxart (VXRT 2.21%) or Ocugen those are going to be higher risk stocks. Back then like a year ago, everything was like that because we didn't know what was going to happen. Whereas now at least you have the safer players and you have the ones that could represent big gains in the future. But for now might be a bit risky.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus owns shares of Moderna Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$2.84 (5.97%) $0.16
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.18 (-0.37%) $0.63
Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$4.16 (2.21%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.